Qiagen Overview

  • Year Founded
  • 1984

Year Founded

  • Status
  • Public

  • Employees
  • 5,700

Employees

  • Stock Symbol
  • QGEN

Stock Symbol

  • Investments
  • 62

  • Share Price
  • $49.63
  • (As of Thursday Closing)

Qiagen General Information

Description

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between life sciences and molecular diagnostics applications. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).

Contact Information

Website
www.qiagen.com
Formerly Known As
Diagen
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Qiagen Strasse 1
  • 40724 Hilden
  • Germany
+49 02103
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Discovery Tools (Healthcare)
Stock Exchange
NYS
Vertical(s)
Corporate Office
  • Qiagen Strasse 1
  • 40724 Hilden
  • Germany
+49 02103

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Qiagen Stock Performance

As of 19-Nov-2026, Qiagen’s stock price is $49.63. Its current market cap is $10.2B with 206M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$49.63 $49.56 $32.53 - $57.81 $10.2B 206M 3.66M $1.87

Qiagen Financials Summary

As of 30-Sep-2026, Qiagen has a trailing 12-month revenue of $2.12B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 9,886,343 10,188,562 10,336,581 10,377,145
Revenue 2,115,649 2,089,999 1,978,214 1,965,311
EBITDA 654,681 652,947 300,240 609,563
Net Income 384,932 424,880 83,591 341,303
Total Assets 5,942,470 6,281,232 5,689,622 6,115,190
Total Debt 1,642,855 1,812,372 1,512,541 1,532,062
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Qiagen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Qiagen‘s full profile, request access.

Request a free trial

Qiagen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins.
Biotechnology
Hilden, Germany
5,700 As of 2026

Boston, MA
 

Tucson, AZ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Qiagen Competitors (13)

One of Qiagen’s 13 competitors is Standard BioTools, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Standard BioTools Formerly VC-backed Boston, MA
HTG Molecular Diagnostics Formerly VC-backed Tucson, AZ
Abcam Corporate Backed or Acquired Cambridge, United Kingdom
Oxford Nanopore Technologies Formerly VC-backed Oxford, United Kingdom
Illumina Formerly VC-backed San Diego, CA
You’re viewing 5 of 13 competitors. Get the full list »

Qiagen Patents

Qiagen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026233823-A1 Compositions and methods for pcr-based analysis of methylatable nucleic acids Pending 06-May-2025
WO-2026229325-A1 Microfluidic device and method for preparing at least one liquid sample Pending 28-Apr-2025
WO-2026224400-A1 Urine workflows Pending 25-Apr-2025
EP-4768122-A1 Microfluidic device for handling a fluid sample Pending 27-Dec-2024
EP-4768123-A1 Microfluidic device for handling a fluid sample Pending 27-Dec-2024 B01L3/502723
To view Qiagen’s complete patent history, request access »

Qiagen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Qiagen Investments & Acquisitions (62)

Qiagen’s most recent deal was a Merger/Acquisition with Parse Biosciences for . The deal was made on 01-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Parse Biosciences 01-Dec-2025 Merger/Acquisition Discovery Tools (Healthcare)
Genoox 23-May-2025 Merger/Acquisition Enterprise Systems (Healthcare)
Verogen 03-Jan-2023 Merger/Acquisition Business/Productivity Software
Blirt 11-May-2022 Merger/Acquisition Biotechnology
Glyphic Biotechnologies 19-Jan-2022 Grant Biotechnology
You’re viewing 5 of 62 investments and acquisitions. Get the full list »

Qiagen ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

13.05 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 67

Rank

Percentile

To view Qiagen’s complete esg history, request access »

Qiagen Exits (16)

Qiagen’s most recent exit was on 07-Jan-2019 from Ellume. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Ellume 07-Jan-2019 Completed
ArcherDX 20-Mar-2018 Completed
  • 5 buyers
Exosome Diagnostics 07-Jan-2016 Completed
  • 7 buyers
Biotype Innovation 04-Sep-2015 Completed
  • 2 buyers
AdnaGen 17-Mar-2015 Merger/Acquisition Completed
You’re viewing 5 of 16 exits. Get the full list »

Qiagen Affiliates

Subsidiaries (5)

Name Industry Location Year Founded
Qiagen Monheim Monheim am Rhein, Germany 2019
Parse Biosciences Seattle, WA 2018
Verogen San Diego, CA 2017
Genoox Palo Alto, CA 2014
Biobase (Healthcare Services) Wolfenbuettel, Germany 1997

Qiagen FAQs

  • When was Qiagen founded?

    Qiagen was founded in 1984.

  • Where is Qiagen headquartered?

    Qiagen is headquartered in Hilden, Germany.

  • What is the size of Qiagen?

    Qiagen has 5,700 total employees.

  • What industry is Qiagen in?

    Qiagen’s primary industry is Biotechnology.

  • Is Qiagen a private or public company?

    Qiagen is a Public company.

  • What is Qiagen’s stock symbol?

    The ticker symbol for Qiagen is QGEN.

  • What is the current stock price of Qiagen?

    As of 19-Nov-2026 the stock price of Qiagen is $49.63.

  • What is the current market cap of Qiagen?

    The current market capitalization of Qiagen is $10.2B.

  • What is Qiagen’s current revenue?

    The trailing twelve month revenue for Qiagen is $2.12B.

  • Who are Qiagen’s competitors?

    Standard BioTools, HTG Molecular Diagnostics, Abcam, Oxford Nanopore Technologies, and Illumina are some of the 13 competitors of Qiagen.

  • What is Qiagen’s annual earnings per share (EPS)?

    Qiagen’s EPS for 12 months was $1.87.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process